Published in Cancer Weekly, October 7th, 1996
Tumor killing by the bystander effect of HSVtk/GCV suicide gene therapy has been reported in several different types of malignant tumors. However, it has not been reported in hematologic malignancies such as plasma cell tumors.
Swedish researchers M. Sirac Dilber et al. demonstrated that a bystander effect can be obtained both in vitro and in vivo in myeloma cells ("Suicide Gene Therapy for Plasma Cell Tumors," Blood, September 15, 1996;88(6):2192-2200).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.